Acedo Pilar, Zawacka-Pankau Joanna
Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Nobels väg 16, 171 77 Stockholm, Sweden.
Photochem Photobiol Sci. 2015 Aug;14(8):1390-6. doi: 10.1039/c5pp00251f. Epub 2015 Jul 23.
TP53 is one of the genes most frequently inactivated in cancers. Mutations in TP53 gene are linked to worse prognosis and shorter overall survival of cancer patients. TP53 encodes a critical tumor suppressor, which dictates cell fate decisions upon stress stimuli. As a sensor of cellular stress, p53 is a relevant messenger of cell death signaling in ROS-driven photodynamic therapy (PDT) of cancer. The significant role of p53 in response to PDT has been reported for several clinically approved photosensitizers. Multiple reports described that wild-type p53 contributes to cell killing upon photodynamic therapy with clinically approved photosensitizers but the mechanism is still not fully understood. This work outlines the diverse functions of p53 family members in cancer cells' susceptibility and resistance to PDT. In summary p53 and p53 family members are emerging as important mediators of cell death signaling in photodynamic therapy of cancer, however the mechanism of cell death provoked during PDT might differ depending on the tissue type and the photosensitizer applied.
TP53是癌症中最常发生失活的基因之一。TP53基因的突变与癌症患者更差的预后和更短的总生存期相关。TP53编码一种关键的肿瘤抑制因子，它在应激刺激时决定细胞命运。作为细胞应激的传感器，p53是癌症的活性氧驱动光动力疗法（PDT）中细胞死亡信号的相关信使。对于几种临床批准的光敏剂，p53在响应PDT中的重要作用已有报道。多项报告描述了野生型p53在临床批准的光敏剂光动力疗法中有助于细胞杀伤，但其机制仍未完全了解。这项工作概述了p53家族成员在癌细胞对PDT的敏感性和抗性中的多种功能。总之，p53和p53家族成员正在成为癌症光动力疗法中细胞死亡信号的重要介质，然而PDT期间引发的细胞死亡机制可能因组织类型和应用的光敏剂而异。
